地特胰岛素联合瑞格列奈对初发2型糖尿病疗效的观察

Efficacy of Insulin Detemir Combined Repaglinide in Treatment of Type 2 Diabetes Patients

目的:评价地特胰岛素联合瑞格列奈对初发2型糖尿病患者血糖和体重的影响。方法:初发2型糖尿病患者60例,随机分为两组,分别于睡前皮下注射地特胰岛素(n=30)或甘精胰岛素(n=30)。两组均联合口服瑞格列奈(1mg,3次/d)治疗12周,比较两组治疗前后空腹血糖(FPG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbA1c)、体重、低血糖的变化。结果:与治疗前比较,两组FPG、2hPG、HbA1c均明显下降,差异均有统计学意义(P<0.05)。两组低血糖发生率差异无统计学意义(P>0.05),而地特胰岛素组体重增加明显低于甘精胰岛素组(P<0.05)。结论:对初发2型糖尿病,与甘精胰岛素相比,地特胰岛素联合瑞格列奈可有效控制血糖,在减少体重增加方面更有优势。

Objective：To evaluate the influence of insulin detemir combined repaglinide on blood sugar and weight in onset type 2 diabetes patients. Method：60 cases onset of type 2 diabetes patients were randomly divided into two groups, subcutaneous injection detemir group （n=30） and insulin glargine group （n=30） respectively in bedtime. Both groups combined oral repaglinide （1 mg,tid） through 12 weeks treatment and to compare the change of fasting plasma glucose （FPG）, 2 h postprandial plasma glucose （2 h PG）, glycated hemoglobin （HbA1c）, weight, incidence of hypoglycemia before and after treatment.Result：Compared with before treatment, FPG, 2 h PG, HbA1c in both groups were significantly decreased, and the differences were statistically significant （P0.05）.The incidence of hypoglycemia between two groups had no significant difference（P0.05）,and the weight gain in detemir group was significantly lower than the insulin glargine group （P0.01）. Conclusion：Regardless of Detemir or insulin glargine combined repaglinide can control blood glucose effectively for the onset of type 2 diabetes patients, detemir is more advantages in reducing weight gain.